Search clinical trials for: lesogaberan (AZD3355)

Total 68 results

AstraZeneca

Completed

Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

Gastroesophageal Reflux Disease | Heartburn | Regurgitation

United States
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan

Unknown

Lesogaberan in Chinese Patients With Refractory Reflux Symptoms

Gastroesophageal Reflux Disease

Taiwan
AstraZeneca

Recruiting

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

Ovarian Cancer | Lung Adenocarcinoma

Spain, China, United States, Australia, Taiwan, Canada, Israel, Japan, United Kingdom
AstraZeneca

Completed

Study to Compare Different Formulations of AZD3355

Gastroesophageal Reflux Disease

Sweden
AstraZeneca

Completed

TLESR-impedance Study in Patients

Reflux Episodes
AstraZeneca

Completed

Renal Impairment Study

Reflux | Renal Excretion

Sweden
AstraZeneca

Completed

AZD3355 Dose-escalation Study in Healthy Males

Reflux Disease

Sweden
AstraZeneca

Completed

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Gastroesophageal Reflux Disease (GERD)

Hungary, Romania, Norway, Belgium, France, Netherlands, Germany, Australia
AstraZeneca

Completed

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms (C27)

GERD | Heartburn | Acid Reflux Disease | Regurgitation

United States
AstraZeneca

Completed

Drug Interaction Study Between AZD3355 and Nexium

Gastroesophageal Reflux Disease

Sweden
AstraZeneca

Completed

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Gastroesophageal Reflux Disease

United States
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
AstraZeneca

Suspended

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

Metabolism | Absorption | Distribution | Excretion

United Kingdom
AstraZeneca

Completed

AZD7325 Multiple Ascending Dose Study (MAD)

Healthy Volunteer

United States
AstraZeneca

Completed

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305 (2007-005765-38)

Healthy

United Kingdom
AstraZeneca

Active, not recruiting

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

COVID-19

United States
AstraZeneca

Completed

Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Atrial Fibrillation

Sweden, Czech Republic, Hungary, Poland, Netherlands, Norway, Denmark, Slovakia
AstraZeneca

Completed

Explorative Study of AZD1305 in Atrial Fibrillation Patients

Atrial Fibrillation

Russian Federation, Poland, Denmark, Norway, Slovakia, Sweden
AstraZeneca

Active, not recruiting

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

COVID-19, SARS-CoV-2

Japan
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

Healthy Participants

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Idiopathic Pulmonary Fibrosis

United States
AstraZeneca

Completed

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Anxiety Disorders

United States
AstraZeneca

Completed

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

Healthy

Sweden
AstraZeneca

Completed

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects (JSAD)

Healthy Volunteer

United States
University College, London

Completed

Effects of GABA Modulator AZD7325 on Cortical Excitability

Healthy

United Kingdom
AstraZeneca

Active, not recruiting

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
AstraZeneca

Completed

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Healthy

United Kingdom
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, Germany, China, Japan
LYZZ Alpha Holding Ltd
Tigermed Consulting Co., Ltd

Completed

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Non Small Cell Lung Cancer

China
AstraZeneca

Completed

Cardiac Electrophysiological Study

Atrial Flutter

Finland, Norway, Denmark, Sweden
AstraZeneca

Completed

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

Healthy

United Kingdom
Children's Hospital Medical Center, Cincinnati

Completed

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

Fragile X Syndrome

United States
AstraZeneca

Completed

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca
Parexel

Completed

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Healthy Volunteers

United States
AstraZeneca

Completed

A Study of Tor Kinase Inhibitor in Advanced Tumors

Solid Tumors

United States, France, United Kingdom
AstraZeneca

Terminated

AZD7325 Japan Multiple Ascending Dose (MAD) Study (JMAD)

Healthy
AstraZeneca

Terminated

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects (JMAD)

Healthy

United States
AstraZeneca

Completed

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Left Ventricle Function

Sweden
AstraZeneca

Completed

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

Healthy

Sweden
National Cancer Institute (NCI)

Completed

AZD8055 for Adults With Recurrent Gliomas

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Brainstem Glioma

United States
University of California, Los Angeles

Completed

Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial (FAST-AS)

Autism Spectrum Disorder

United States
University College, London

Completed

Effects of GABA Modulator AZD7325 on Cutaneous Sensation

Healthy

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Cancer | Advanced Hepatocellular Carcinoma

Korea, Republic of, Hong Kong
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca

Withdrawn

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

Cancer | Advanced Solid Tumours | Lymphomas
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
AstraZeneca
Parexel

Terminated

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Healthy Subjects

United Kingdom
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
AstraZeneca

Completed

An Interaction Study With Digoxin and AZD1305

Atrial Fibrillation

Sweden

3

Subscribe